Article Versions Notes

Cosentino-Boehm AL, Lafky JM, Greenwood TM, Kimbler KD, Buenafe MC, Wang Y, Branscum AJ, Yang P, Maihle NJ, Baron AT. Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma. Diagnostics. 2013; 3(1):13-32. https://doi.org/10.3390/diagnostics3010013

Cosentino-Boehm, Abby L., Jacqueline M. Lafky, Tammy M. Greenwood, Kimberly D. Kimbler, Marites C. Buenafe, Yuxia Wang, Adam J. Branscum, Ping Yang, Nita J. Maihle, and Andre T. Baron. 2013. "Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma" Diagnostics 3, no. 1: 13-32. https://doi.org/10.3390/diagnostics3010013

Cosentino-Boehm, A. L., Lafky, J. M., Greenwood, T. M., Kimbler, K. D., Buenafe, M. C., Wang, Y., Branscum, A. J., Yang, P., Maihle, N. J., & Baron, A. T. (2013). Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma. Diagnostics, 3(1), 13-32. https://doi.org/10.3390/diagnostics3010013